Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41859 CARGO Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 84-4080422 (State or ...

CARGO Therapeutics, Inc. (CRGX) has been on a downward spiral lately with significant selling pressure. After declining 69.6% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting ...

The price trend for CARGO Therapeutics, Inc. (CRGX) has been bearish lately and the stock has lost 6% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor ...

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ: CRGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Cargo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On or around Novembe ...

Investors might want to bet on CARGO Therapeutics, Inc. (CRGX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a ...

LOS ANGELES, Jan. 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ: CRGX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. CARGO announced in a press release issued on January 29, 2025, that it "has ...

LOS ANGELES, Jan. 30, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ: CRGX) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. A CARGO press release dated January 29, 2025, indicates that it will discontinue FIRCE-1, a Phase 2 clinical study ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to implement a workforce reduction of approximately 50%.Phase 1 dose escalation study enrollment for CRG-023 on track to initiate in Q2 2025. SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially ...

Clinical Trials and Study Progress - 71 patients have been dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel), with interim analysis results expected in 1H'25[4] - FDA cleared the IND application for CRG-023, a tri-specific CAR T, with Phase 1 study enrollment expected to initiate mid-year 2025[4] - CRG-023 Phase 1 study will begin at a dose level of 25 million cells, informed by preclinical data showing in vivo tumor clearance at low dose levels[6] - CARGO expects to share topline data from an interim analysis of firi-cel with at least 3 months of follow-up in 1H'25[10] CAR T-Cell Therapy Development - CARGO's novel allogeneic platform is designed to limit immune-based rejection and enable durable response of CAR T-cell therapy, with lead vector candidate selection expected in 1H'25[7] - CRG-023 is a first-of-its-kind CAR T to express three independent CARs (CD19, CD20, CD22) from a single vector, each with a distinct co-stimulatory domain[10] - The novel allogeneic platform aims to transform autologous CAR T-cell therapies into allogeneic products, leveraging existing autologous drug product processes[7] - CRG-023 drug product is produced using CARGO's internally developed process and analytical methods, with a suspension culture process providing commercially suitable expression levels[10] Strategic Plans and Financials - CARGO plans to leverage proof-of-concept data from CRG-023 to support moving quickly into earlier lines of therapy and additional indications in B-cell malignancies[10] - CARGO's preliminary cash, cash equivalents, and marketable securities were $368.1 million as of December 31, 2024, expected to fund operations through 2026[11]

- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 - - IND application for CRG-023, CARGO’s tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 - - CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new or existing CAR vector to create an allogeneic CAR T-cell therapy while l ...